Kataoka H, Nabeshima K, Komada N, Koono M
Department of Pathology, Miyazaki Medical College, Japan.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):157-65. doi: 10.1007/BF02899077.
Two new human cell lines, RCM-1 and CoCM-1, have been established from primary colorectal adenocarcinomas. Both cell lines were unique in that the cultures secreted trypsin inhibitors in vitro. The activities of these inhibitors were accumulated in serum-free media of both cell lines over a period of several days. Two inhibitors (PI-1 and PI-2) were isolated from serum-free conditioned medium in which RCM-1 was grown by anion-exchange and gel filtration high-performance liquid chromatography. PI-1 inhibited trypsin and chymotrypsin strongly, and pancreatic elastase weakly. Its molecular weight was about 57 kilodaltons (Kd) as determined by gel filtration chromatography. It cross-reacted with the antiserum elicited against human alpha 1-antitrypsin in double immunodiffusion. PI-1 corresponding to alpha 1-antitrypsin was also demonstrated immunohistochemically in both cell lines. PI-2 inhibited trypsin strongly, and chymotrypsin, kallikrein and plasmin weakly. It had higher molecular weight (200-300 Kd) than that of PI-1, and did not cross-react with antisera against human alpha 1-antitrypsin, alpha 2-macroglobulin, alpha 1-antichymotrypsin, alpha 2-plasmin inhibitor, inter-alpha-trypsin inhibitor and urinary trypsin inhibitor. RCM-1 and CoCM-1 are the first colorectal adenocarcinoma cell lines that secrete functionally active trypsin inhibitors, including alpha 1-antitrypsin in vitro, and are useful for the study of tumor-cell derived proteinase inhibitors.
已从原发性结肠直肠癌中建立了两种新的人类细胞系,即RCM-1和CoCM-1。这两种细胞系的独特之处在于,其培养物在体外分泌胰蛋白酶抑制剂。在数天时间内,这些抑制剂的活性在两种细胞系的无血清培养基中积累。从RCM-1生长的无血清条件培养基中,通过阴离子交换和凝胶过滤高效液相色谱法分离出两种抑制剂(PI-1和PI-2)。PI-1强烈抑制胰蛋白酶和糜蛋白酶,对胰弹性蛋白酶的抑制作用较弱。通过凝胶过滤色谱法测定,其分子量约为57千道尔顿(Kd)。在双向免疫扩散中,它与抗人α1-抗胰蛋白酶产生的抗血清发生交叉反应。在两种细胞系中,通过免疫组织化学也证实了与α1-抗胰蛋白酶相对应的PI-1。PI-2强烈抑制胰蛋白酶,对糜蛋白酶、激肽释放酶和纤溶酶的抑制作用较弱。它的分子量比PI-1高(200 - 300 Kd),并且不与抗人α1-抗胰蛋白酶、α2-巨球蛋白、α1-抗糜蛋白酶、α2-纤溶酶抑制剂、α-胰蛋白酶抑制剂和尿胰蛋白酶抑制剂的抗血清发生交叉反应。RCM-1和CoCM-1是首批在体外分泌具有功能活性的胰蛋白酶抑制剂(包括α1-抗胰蛋白酶)的结肠直肠腺癌细胞系,可用于研究肿瘤细胞衍生的蛋白酶抑制剂。